Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 489-498, 2009. First published January 23, 2009; 10.1373/clinchem.2008.113373
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2008.113373v1
55/3/489    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Semenov, A. G.
Right arrow Articles by Katrukha, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Semenov, A. G.
Right arrow Articles by Katrukha, A. G.
(Clinical Chemistry. 2009;55:489-498.)
© 2009 American Association for Clinical Chemistry, Inc.

Proteomics and Protein Markers

Processing of Pro–Brain Natriuretic Peptide Is Suppressed by O-Glycosylation in the Region Close to the Cleavage Site

Alexander G. Semenov1,a, Alexander B. Postnikov1, Natalia N. Tamm1, Karina R. Seferian1, Natalia S. Karpova2, Marina N. Bloshchitsyna1, Ekaterina V. Koshkina3, Mihail I. Krasnoselsky4, Daria V. Serebryanaya2 and Alexey G. Katrukha1

1 HyTest Ltd., Turku, Finland; 2 Department of Biochemistry, Moscow State University, Moscow, Russia; 3 67 City Hospital, Moscow, Russia; 4 Moscow State Medico-Stomatological University, Moscow, Russia.

aAddress correspondence to this author at: HyTest Ltd., Intelligate, 6th Floor, Joukahaisenkatu 6, 20520 Turku, Finland. Fax 358-25120909; e-mail alexander.semenov{at}hytest.fi.

Background: Processing of the brain natriuretic peptide (BNP) precursor, proBNP, is a convertase-dependent reaction that produces 2 molecules—the active BNP hormone and the N-terminal part of proBNP (NT-proBNP). Although proBNP was first described more than 15 years ago, very little is known about the cellular mechanism of its processing. The study of proBNP processing mechanisms is important, because processing impairments could be associated with the development of heart failure (HF).

Methods: The biochemical properties of recombinant proBNP and NT-proBNP and the same molecules derived from the blood of HF patients were analyzed by gel-filtration chromatography, site-directed mutagenesis, and different immunochemical methods with a panel of monoclonal antibodies (MAbs).

Results: Part of the proBNP molecule (amino acid residues 61–76) located near the cleavage site was inaccessible to specific MAbs because of the presence of O-glycans, whereas the same region in NT-proBNP was completely accessible. We demonstrated that a convertase (furin) could effectively cleave deglycosylated (but not intact) proBNP. Of several mutant proBNP forms produced in a HEK 293 cell line, only the T71A variant was effectively processed in the cell.

Conclusions: Only proBNP that was not glycosylated in the region of the cleavage site could effectively be processed into BNP and NT-proBNP. Site-directed mutagenesis enabled us to ascertain the unique suppressing role of T71-bound O-glycan in proBNP processing.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
J. Mair
Clinical Significance of Pro-B-Type Natriuretic Peptide Glycosylation and Processing
Clin. Chem., March 1, 2009; 55(3): 394 - 397.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.